ArticleFrontiers in pharmacology2024

Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer.

Mulan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.